Accession has created subnational access programmes that help translate scientific innovation into real-world practical patient access in the NHS for ophthalmology services.

Accession was born from a passion and a vision. A passion to harness the power of market access to ensure patients gain access to life changing medicines. A vision to make a positive impact on the success of our clients, the economy and the wider society. It’s a passion that provides the beating heart of everything we do, and a vision that lives on in our company today, alongside our unwavering values of quality and excellence, as we push the boundaries of our work in market access consulting. Accession delivers value and access services to the world’s largest biopharma companies. As pioneers in the use of digital technology in market access, Accession’s proprietary digital products are transforming how their clients work, compete in the market and engage with their customers. Accession was named as “One to Watch” in the 2020 Alantra Pharma Fast 50, an annual ranking of the UK’s fastest-growing privately-owned pharma companies. In March 2021 Accession received private investment from a group of highly experienced healthcare and technology investors to support its continued strong performance and ambitious growth plans. The investment will be used to accelerate Accession’s track record and focus on using digital technology to disrupt the status quo in their sector and to supercharge the ongoing international expansion of their core products and services. Together we can accelerate your innovation process and disrupt the status quo. Your customers and their patients will thank you for it.

Founded 2011